A daytime approach to an undertreated health problem.
REMA Sleep is developing a non-invasive device for obstructive sleep apnea, built on resonant technology and led by a founder with a track record of bringing airway innovation to market.
Sleep apnea is common, serious, and largely undiagnosed.
Obstructive sleep apnea affects a large share of the population, yet most cases are never identified or treated. Left unmanaged, it is linked to serious downstream conditions.
Untreated obstructive sleep apnea has been associated with stroke, heart attack, diabetes, and depression,4 making earlier and easier intervention a meaningful clinical goal.
A different way to condition the airway.
Non-invasive and worn while awake
The device is worn around the neck for roughly 30 minutes during the day, not overnight.
Resonant technology
It is designed to condition the airway using a resonant mechanotherapy approach.
Designed to be simple and accessible
The approach aims to be easy to use and low cost relative to existing options.
On a defined regulatory pathway
The device is being pursued through the FDA 510(k) pathway.
The opportunity sits inside what we believe to be a sizeable and expanding market for sleep apnea devices, with an established regulatory route.
Founder-led, with established airway experience.
Dr. Dave Singh, DMD PhD DDSc
Interested in learning more?
Detailed materials are shared directly with qualified interested parties on request.
Request additional informationReferences
- Finkel KJ, et al. Prevalence of undiagnosed obstructive sleep apnea among adult surgical patients in an academic medical center. Sleep Med. 2009. https://pubmed.ncbi.nlm.nih.gov/19186102/. Also Boers et al. Projecting the 30-year burden of obstructive sleep apnea in the United States. CHEST. 2025. https://doi.org/10.1016/j.chest.2025.03.029.
- Boers et al. Projecting the 30-year burden of obstructive sleep apnea in the United States. CHEST. 2025. https://doi.org/10.1016/j.chest.2025.03.029.
- Aloia MS, et al. Clinical management of poor adherence to CPAP: motivational enhancement. Behav Sleep Med. 2004;2(4):205-222. https://doi.org/10.1207/s15402010bsm0204_3.
- Mitra et al. Association and risk factors for obstructive sleep apnea and cardiovascular diseases: A systematic review. Diseases. 2021. https://doi.org/10.3390/diseases9040088.
- Singh GD, Sabet J, Wood S, Battle J. Pharyngeal biostimulation for the treatment of obstructive sleep apnea. Sleep. 2025;48(1):161. Also Singh GD, Wood S, Sabet J. Effect of pharyngeal biostimulation on the upper airway in adults. J Clin Sleep Med. 2026;22:96.
- Data Bridge Market Research, Global Sleep Apnea Devices Market (market valued at USD 4.78 billion in 2024 and projected to reach USD 8.66 billion by 2032, CAGR 7.70%). https://www.databridgemarketresearch.com/reports/global-sleep-apnea-devices-market (accessed August 2026).
- Boers et al. Projecting the 30-year burden of obstructive sleep apnea in the United States. CHEST. 2025. https://doi.org/10.1016/j.chest.2025.03.029.
This page is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security in any jurisdiction. Any such offer or solicitation will be made solely through REMA's confidential offering memorandum or similar formal investment documentation, in strict accordance with the terms of all applicable securities laws and regulations.
No information, statements, or analyses presented on this site or in REMA materials are intended to form the basis of any investment decision, nor do they constitute investment advice, recommendations, or counsel. This material does not constitute or form part of, and should not be construed as, any offer for sale or subscription, or any invitation to offer to buy or subscribe for any securities, nor should it or any part of it form the basis of, or be relied upon in connection with, any contract or commitment of any kind.
REMA expressly disclaims any and all liability for any direct or consequential loss or damage arising directly or indirectly from: (i) reliance on any information provided here or in related materials; (ii) any error, omission, or inaccuracy in such information; or (iii) any action taken or decision made based on such information.
Securities-related services offered through Exemplar Capital, LLC, Member FINRA/SIPC. The REMA device is under development and referenced research is preliminary; nothing here should be read as a claim of clinical efficacy or regulatory clearance.
"Safe Harbor" for Forward-Looking Statements
Certain information set forth herein contains "forward-looking information", including "future-oriented financial information" and "financial outlook", under applicable securities laws (collectively referred to herein as forward-looking statements), which may describe strategies, goals, outlook or other non-historical matters, or project revenues, income, returns or other financial measures, often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "guidance," "project," "target," "potential," "will," "should," "could," "likely," or "may" and similar expressions intended to identify forward-looking statements. These statements are only speculative predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) the expected development of the Company's business, projects, research, and joint ventures; (iii) execution of the Company's vision and growth strategy, including with respect to future production, sales, merger and acquisition activity, and market growth; (iv) sources and availability of third-party financing for the Company's projects and research; (v) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vi) regulatory approval of and commercial viability of Company's expected products; and (vii) future liquidity, working capital, and capital requirements.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained herein are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are not guarantees of future performance or outcomes and speak only as of the date on which they are made, and the Company undertakes no obligation to update or revise any forward-looking statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
The information and market and statistical data contained in this presentation has been taken from independent research firms, publicly available information, various industry publications, other published industry sources or our internal data and estimates. The methodologies for collecting information and data from these sources, and therefore the information discussed in this section, may differ from those of other sources, and do not reflect all or even necessarily a comprehensive set of relevant information and market and statistical data. Independent research reports, industry publications and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. Although the Company believes the sources cited to be reliable, it has not taken steps to independently verify the information from third parties set forth herein.